3GILD : Gilead Sciences Unusual Options Activity
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Gilead announces European Medicines Agency validation for lenacapavir
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
stocknews2h
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
emjreviews.com7h
EMA grants accelerated review to Gilead’s PrEP drug
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
GlobalData on MSN6d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
What Analysts Think of Salesforce Stock Ahead of Earnings
Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on the cloud-based software company's stock, anticipating AI-driven gains.
MarketBeat on MSN2d
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...